Trials 1/2020

Cancer research · NSCLC

Abstract not provided.

Evidence level: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.

Original source

Related signals

• Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
• Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
• Recent advancements in lung cancer research: a narrative review
• Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
• Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT